Position:Index » news » R&D updates

WuXi Biologics to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

2018-05-02

An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over five years in a new biologics drug substance manufacturing facility on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth.

Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.、

This state-of-the-art “facility of the future” will be built upon the novel approach WuXi Biologics has pioneered deploying multiple single-use bioreactors for commercial biomanufacturing and is also designed to be able to run continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this campus. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed, representing the world’s largest facility using single-use bioreactors.

The manufacturing project in a 26-hectare campus, the company’s first site outside of China, is supported by the Irish Government through IDA Ireland.(WuXi biologics)


Contact us

Headquarters: RM. 1314-1315, JINJUN PLAZA, 341,SHUIXIANG RD.,JIANGANG,HANGZHOU,CHINA,310020.

Tel: 0086-571-86539525/26/27/29

Fax:0086-571-86539526

Email: kaixin@hzkaixin.com

Copyright 2017 Hangzhou KAIXIN technology limited company Copyright Technical support:Lanyunwork